|
|||||||
|
|
|
|||||
|
|
|||||||
Curriculum Vitae
of Jonas Cicenas
Last name:Cicenas
First name:Jonas
Date and place of birth: December 17, 1974; Klaipeda, Lithuania.
Citizenship:Lithuania.
Education:
1982-1993:Klaipeda School #19;
1993-1997 and 1997-1999: Faculty of Natural Sciences,Vilnius Pedagogical University(biology);
1997: Bachelor's degree in natural sciences;
1999: Master's degree in natural sciences.
1999-2000Dept. Anatomy and Cell Biology, East Carolina University School of Medicine
2002-2004: ,University of Basel
2004: PhD in Biochemistry
Research and technical experience:
1996-1997: Institute of Immunology, Lithuania (undergraduate student);
1997-1999: Institute of Biochemistry, Lithuania (laboratory assistant);
1999-2000:Dept. Anatomy and Cell Biology, East Carolina University School of Medicine, Greenville, NC, USA (PhD student).
2002-2004: Department of Research, Kantonspital Basel & Stiftung Tumorbank Basel, Basel, Switzerland (PhD student)
2005-2007: DKV Clinical Immunology, University of Bern, Bern, Switzerland (postdoc)
Publications
Cicenas J.The potential role of Akt phosphorylation in human cancers.-Int J Biol Markers. 2008 Jan-Mar;23(1):1-9.ReviewFONT>
Cicenas J.The potential role of the EGFR/ERBB2 heterodimer in breast cancer.-Expert opinion Ther. Patents. 2007; 17(6): 607-16. Review
Weissenstein U, Schneider MJ, Pawlak M, Cicenas J, Eppenberger-Castori S, Oroszlan P, Ehret S, Geurts-Moespot A, Sweep FC, Eppenberger U.Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.-Proteomics. 2006 Mar;6(5):1427-36.
Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S.Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.-Eur J Cancer. 2006 Mar;42(5):636-45.
Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S.Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.-Breast Cancer Res. 2005;7(4):R394-401. Epub 2005 Mar 24.
